Navacaprant
Navacaprant (BTRX-335140) is a selective and orally active κ opioid receptor (KOR) antagonist, has antagonist activity for κOR, μOR and δOR with IC50 values of 0.8 nM, 110 nM, and 6500 nM, respectively. Navacaprant endows with favorable in vitro ADMET and in vivo pharmacokinetic profiles and medication-like duration of action in rats. Navacaprant distributes well into the CNS and can be used for the research of neuropathy[1].
Product Specifications
CAS Number
2244614-14-8
Product Name Alternative
BTRX-335140; CYM-53093
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Opioid Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/navacaprant.html
Purity
99.97
Solubility
1 M HCl : 3.33 mg/mL (ultrasonic) |DMSO : 3.85 mg/mL (ultrasonic; warming; adjust pH to 4 with HCl; heat to 60°C)
Smiles
CC1=NOC(C2=C(C)C3=CC(CC)=CC(F)=C3N=C2N4CCC(NC5CCOCC5)CC4)=N1
Molecular Formula
C25H32FN5O2
Molecular Weight
453.56
Precautions
H302, H315, H319
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
δ Opioid Receptor/DOR; κ Opioid Receptor/KOR; μ Opioid Receptor/MOR
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
